Elite Pharmaceuticals Reports Topline Results from a Pivotal Fed Bioequivalence Study for SequestOx™
July 07, 2017 12:47 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., July 07, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported topline results from a pivotal bioequivalence fed study for...
Elite Pharmaceuticals Reports Positive Topline Results from a Pivotal Bioequivalence Study for a Generic OxyContin®
January 17, 2017 08:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J, Jan. 17, 2017 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (OTCBB:ELTP) today reported positive topline results from a pivotal bioequivalence fed study...
Elite Pharmaceuticals Reports Results of Pilot Bioequivalence Study for ELI-201
February 18, 2014 07:00 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Feb. 18, 2014 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today successful results from a pilot bioequivalence study...
Elite Pharmaceuticals Initiates Pilot Bioequivalence Study for ELI-201
December 05, 2013 12:49 ET
|
Elite Pharmaceuticals, Inc.
NORTHVALE, N.J., Dec. 5, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") ("Elite") (OTCBB:ELTP) announced today the first dosing of a pilot bioequivalence study in...